Novartis Pharma Ag competitive analysis

Explore patent oppositions filed by Novartis Pharma Ag against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026
Patent NumberTitleApplicantOpposition Date
Method Of Detecting Polymorphs Using Synchrotron RadiationZACH SYSTEMApr 27, 2017
Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 AntibodyBIOGENJan 29, 2016

Explore Novartis Pharma Ag's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 10, 2026
Patent NumberPublication DateTitleTotal Oppositions
Mar 26, 2025Tablets Comprising Eltrombopag Olamine3
Jan 15, 2025A Rapamycin Derivative For Treating Lung Cancer7
Jul 3, 2024Novel Pharmaceutical Composition7
Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof6
Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid Tumours3
Jul 22, 2020Combination Therapies For Cancer1
Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor8
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis10
Aug 21, 2019Rapamycin Derivative For Treating Pancreas Cancer10
Mar 7, 2018Tuberous Sclerosis Treatment4

Latest PTAB cases involving Novartis Pharma Ag

Discover the latest PTAB cases involving Novartis Pharma Ag, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Novartis Pharma Ag with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
NOVARTIS12542 - 21
GENERICS UK319 - - -
STADA ARZNEIMITTEL15429 - -
TEVA PHARMACEUTICAL INDUSTRIES LTD2717 - -